Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by GenericAdvocateon Feb 22, 2017 12:56am
177 Views
Post# 25875522

RE:RE:Useful Actionable information from Hulot............

RE:RE:Useful Actionable information from Hulot............Bahahahahahahaha   RBC analysts put this at $1.00 price target and I think they are being optimistic.  Scotia puts it at 50 cents.  

You must have patience to see this thing tank every day and still be here pumping  it.

As for your balls....  



  1.  
  2. "Balls. Of. Steel. Going to take a bit more than this to make me drop." Crystal Balls to hold $CXRX $CXR.CA

  3.  
     
     




MrHulot wrote:

You want useful information RADish. Here it is:

CXR is a unique opportunity. If you have enough patience and balls, this investment has the potential for huge gains. I have already explained the reasons for the downturn in earlier posts. Bad timing. Bad Luck. Then the Company when into shock and a tailspin. Like a chicken without its head so to speak. You’d know that right, Lattice. Take a look at recent history: With almost the same fundamentals CXR was $65 only 15 months ago. Let's say the company conservatively makes $3 per share as analysts estimate in 2017. 50/3=16.7 PE that is lower than the average PE in the Pharma industry. This is crazy for this stock. Let's assume the market is forward looking, basing a decision on analyst assessments. If leading analysts put 2017 at EPS $3, then why are market estimates giving a share price below $3? Huge opportunity. Any chance for Bankruptcy? Sure, but not earlier than four years. If Bankruptcy is not on the horizon than I conclude THIS IS THE CHEAPEST PHARMA STOCK ON THE PLANET.



<< Previous
Bullboard Posts
Next >>